Lenvatinib Clinical Trials (75 Recruiting)

Showing 1–20 of 82 trials

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Esophageal Squamous Cell Carcinoma

Merck Sharp & Dohme LLC230 enrolled59 locationsNCT05319730

Recruiting

Phase 3

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid TumorsHematologic Malignancies

Merck Sharp & Dohme LLC3,500 enrolled782 locationsNCT03486873

Recruiting

Phase 3

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Metastatic Clear Cell Renal Cell Carcinoma+1 more

SWOG Cancer Research Network718 enrolled41 locationsNCT07383441

Recruiting

Phase 2

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

Canadian Cancer Trials Group140 enrolled12 locationsNCT06880523

Recruiting

Phase 2

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Sichuan Baili Pharmaceutical Co., Ltd.74 enrolled1 locationNCT06986785

Recruiting

Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Solid Tumor

Eisai Inc.182 enrolled58 locationsNCT04300556

Recruiting

Phase 2

Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy

Hepatocellular Carcinoma (HCC)

CHA University80 enrolled1 locationNCT07493668

Recruiting

Phase 1Phase 2

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more

GI Innovation, Inc.317 enrolled12 locationsNCT04977453

Recruiting

Phase 1Phase 2

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center54 enrolled7 locationsNCT06110793

Recruiting

Phase 2

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Recurrent Endometrial Cancer

University of Miami46 enrolled1 locationNCT07594015

Recruiting

Phase 2

Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Recurrent Vulvar CancerPersistent Vulvar CancerMetastatic Vulva Cancer+1 more

AGO Research GmbH42 enrolled15 locationsNCT05903833

Recruiting

Phase 2

Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma

Clear Cell RCC

Jinling Hospital, China75 enrolled1 locationNCT07571551

Recruiting

Phase 2

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Cervical CancerCervix Cancer

University of Texas Southwestern Medical Center30 enrolled1 locationNCT06266338

Recruiting

Phase 2

Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Hepatocellular Carcinoma Resectable

Peking Union Medical College Hospital33 enrolled1 locationNCT07014150

Recruiting

Phase 2

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Metastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8+1 more

NRG Oncology240 enrolled318 locationsNCT05327686

Recruiting

Phase 2

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Unresectable or Metastatic Hepatocellular CarcinomaChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound

CatalYm GmbH104 enrolled2 locationsNCT07219459

Recruiting

Phase 2

A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

Hepato Cellular Carcinoma (HCC)

Fudan University350 enrolled1 locationNCT07328009

Recruiting

Phase 2

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Biliary Tract CancerHepatocellular Carcinoma

AstraZeneca294 enrolled60 locationsNCT05775159

Recruiting

Phase 2

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

Carcinoma, Squamous CellAnorectal Cancer

University of Chicago35 enrolled1 locationNCT06669572

Lenvatinib Clinical Trials

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment